Amicus Therapeutics Inc
NASDAQ:FOLD
Amicus Therapeutics Inc
NASDAQ:FOLD
Price:
10.43 USD
4.4%
Market Closed
Updated:
May 2, 2024
Section:
Relative Value
The Relative Value of one
FOLD
stock under the Base Case scenario is
24.09
USD.
Compared to the current market price of 10.43 USD,
Amicus Therapeutics Inc
is
Undervalued by 57%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
FOLD
Relative Value
Base Case
24.09
USD
Undervaluation 57%
Valuation Multiples
Multiples Across Competitors
FOLD Competitors Multiples
Amicus Therapeutics Inc Competitors
Amicus Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
3.1B USD | 7.7 | -20.2 | -46.4 | -41.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
285.6B USD | 5.3 | 59.3 | 12.9 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
148.5B USD | 5.3 | 22.1 | 16.4 | 24.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.6B USD | 10.5 | 28.6 | 22.9 | 24 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
98.8B USD | 7.5 | 25 | 16.6 | 18.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133B AUD | 6.1 | 35.1 | 21.3 | 26.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 168.6 | 6.8 | 8.9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
42.6B USD | 6.2 | -9 | -9.5 | -8.2 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.5B USD | 3.3 | 27 | 13.8 | 17.3 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.3T KRW | 18.1 | 73.4 | 44.9 | 61.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
